Press Releases

Date Title
Toggle Summary Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
SAN DIEGO , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled to
Toggle Summary Kura Oncology to Present at H.C. Wainwright Global Investment Conference
SAN DIEGO , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the H.C. Wainwright 20 th Annual Global Investment Conference .
Toggle Summary Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
SAN DIEGO , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the 2018 Wedbush PacGrow Healthcare Conference .
Toggle Summary Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming registration-directed trial of tipifarnib in HRAS mutant HNSCC – – Biomarker-enriched Phase 2 trial of
Toggle Summary Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer
Investment banking veteran brings two decades of experience in finance and corporate strategy in the biopharma industry SAN DIEGO , July 31, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for
Toggle Summary Kura Oncology to Report Second Quarter 2018 Financial Results
SAN DIEGO , July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report second quarter 2018 financial results after the close of U.S.
Toggle Summary Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO , July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock, including
Toggle Summary Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
SAN DIEGO , June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions,
Toggle Summary Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell , M.D., and Blake Tomkinson , Ph.D., join as Vice Presidents of Clinical Development – – Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) expected